drugset

drugset / Trial / NCT02191826

Study of SOM0226 in Familial Amyloid Polyneuropathy

NCT02191826 ↗

Phase 1/2 Completed 17 enrolled SOM Innovation Biotech SA Hospital Vall d'Hebron · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis.

Timeline

Start: 2014-07
Primary completion: 2015-11
Completion: 2015-11

Publications

Gamez J, Salvado M, Reig N, Sune P, Casasnovas C, Rojas-Garcia R, Insa R. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid. 2019 Jun;26(2):74-84. doi: 10.1080/13506129.2019.1597702. Epub 2019 May 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SOM0226	Unknown	100 mg	Oral
Subject	SOM0226	Unknown	200 mg	Oral

Indications